Pitstop® 1, Novel clathrin inhibitor (ab120685)
Key features and details
- Novel, selective clathrin inhibitor
- CAS Number: 1332879-51-2
- Soluble in water to 25 mM and in DMSO to 100 mM
- Form / State: Solid
- Source: Synthetic
Product namePitstop® 1, Novel clathrin inhibitor
DescriptionNovel, selective clathrin inhibitor
Novel, selective clathrin inhibitor. Competitively inhibits clathrin terminal domain (TD) to selectively inhibit clathrin mediated endocytosis (IC50 = ~18 μM for inhibition of amphiphysin association of clathrin TD). Interferes with receptor mediated endocytosis, entry of HIV and synaptic vesicle recycling. Exhibits limited cell membrane penetration, however it is active in cells after microinjection.
General notesSold under exclusive licence from Children's Medical Research Institute and Newcastle Innovation Ltd. Pitstop® is a trademark of Freie Universitat Berlin, Newcastle Innovation Ltd. and Children's Medical Research Institute
Chemical name2-(4-Aminobenzyl)-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinoline-5-sulfonic acid sodium salt
Storage instructionsStore at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months.
Solubility overviewSoluble in water to 25 mM and in DMSO to 100 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab120685 has been referenced in 2 publications.
- Gao Y et al. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol 22:1064-1075 (2020). PubMed: 32839551
- Billups D et al. Inducible presynaptic glutamine transport supports glutamatergic transmission at the calyx of held synapse. J Neurosci 33:17429-34 (2013). PubMed: 24174676